Silk Road Medical, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 28, 2024 at 04:07 pm EST
Share
Silk Road Medical, Inc reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 47.27 million compared to USD 40.07 million a year ago. Net loss was USD 13.01 million compared to USD 12.61 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.34 a year ago.
For the full year, sales was USD 177.13 million compared to USD 138.64 million a year ago. Net loss was USD 55.74 million compared to USD 55.01 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.54 a year ago.
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
SILK ROAD MEDICAL, INC 
